"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1999 | 2 | 5 | 7 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 4 | 6 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
-
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. J Manag Care Spec Pharm. 2022 Oct; 28(10):1066-1079.
-
The relationship between financial hardship and incident diabetic kidney disease in older US adults - a longitudinal study. BMC Nephrol. 2021 05 05; 22(1):167.
-
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
-
Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. J Manag Care Spec Pharm. 2020 Jul; 26(7):879-886.
-
The Skyrocketing Cost of Rectal Indomethacin. JAMA Intern Med. 2020 05 01; 180(5):631-632.
-
Costs and cost-drivers of a diagnosis of depression among adults with epilepsy in the United States. Epilepsy Behav. 2019 09; 98(Pt A):96-100.
-
A new side of sarcoidosis: medication and hospitalization use in a privately insured patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2019; 36(2):124-129.
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.